Skip to content Skip to navigation

The New Era of Genome Engineering: How CRISPR-Cas9 is Changing the Policy and Biosecurity Landscape

November 11, 2015 - 5:30pm to 7:30pm
Clark Center S360 (behind Peet's)

We cordially invite the Stanford community to a panel discussion on the policy impacts of the latest genome engineering technologies, led and moderated by world-class scholars in Law, Ethics, Biosecurity, and Stem Cell Biology.

Students of all disciplines with interests in science policy are encouraged to attend. In addition, you can learn more about the Stanford Public Policy program, courses and joint degrees, and opportunities to explore careers in science policy.

The event is free and will take place in Clark Center S360 (behind Peet’s). The panel discussion will commence at 6pm, preceded by a reception and refreshments at 5:30pm. Event details can be found in the flyer below. 

We hope you'll be able to join us—please RSVP here by November 8th and contact ywli@stanford.edu with any questions.

More about the panelists:

Milana Boukhman, MD MBA is a Clinical Associate Professor of Surgery, Division of Emergency Medicine, at Stanford Medical School. She is an expert on Emergency Medicine, Biosecurity, and Bioweapons. She graduated from the University of California San Francisco School of Medicine and completed her emergency medicine training at the Harvard Affiliated Emergency Medicine Residency/BI Deaconess Hospital. In addition, she teaches the popular course "Biosecurity and Bioterrorism Response" at Stanford University.

Henry T. Greely, JD specializes in the ethical, legal, and social implications of new biomedical technologies, particularly those related to neuroscience, genetics, or stem cell research. He graduated from Stanford University in 1974 and completed his JD at Yale Law School in 1977. He is the Deane F. and Kate Edelman Johnson Professor of Law, Director of the Center for Law and the Biosciences, and by courtesy Professor of Genetics. In addition, he is the chair of the Steering Committee of the Center for Biomedical Ethics, the director of the Stanford Program in Neuroscience and Society, chair of California’s Human Stem Cell Research Advisory Committee, a member of the Advisory Council of the NIH’s National Institute for General Medical Sciences, a member of the Committee on Science, Technology, and Law of the National Academies, among others.

Marius Wernig, MD is an Associate Professor of Pathology and, by courtesy, Chemical and Systems Biology. He is a world-class expert in stem cell biology and specializes in mechanisms underlying cell fate determination; his lab utilizes defined factors to reprogram cells from one cell type to another. For example, his lab directly converted fibroblasts into functional neuronal cells. Dr. Wernig received his M.D. from Technical University of Munich in Germany.